Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Summary

The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.

Timeline

Start

2009-09

Primary completion

2014-01

Completion

2014-01

Outcome

Missed primary endpoint

paper no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point PMID 25176136 ↗

registry Ivabradine vs Placebo; p = 0.1969; Cox Proportional Hazard 1.08 (95% CI 0.96 to 1.2) NCT02446990 ↗

Publications

• Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.
• Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013 Oct;166(4):654-661.e6. doi: 10.1016/j.ahj.2013.06.024. Epub 2013 Sep 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivabradine	Small molecule	5 mg	Oral
Subject	Ivabradine	Small molecule	7.5 mg	Oral
Subject	Ivabradine	Small molecule	10 mg	Oral

Indications